Cargando…
CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
Graves’ disease, an autoimmune disease with heterogeneous symptoms including Graves’ orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers. Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225215/ https://www.ncbi.nlm.nih.gov/pubmed/27638540 http://dx.doi.org/10.1007/s12020-016-1096-1 |
_version_ | 1782493475942432768 |
---|---|
author | Pawlak-Adamska, Edyta Frydecka, Irena Bolanowski, Marek Tomkiewicz, Anna Jonkisz, Anna Karabon, Lidia Partyka, Anna Nowak, Oskar Szalinski, Marek Daroszewski, Jacek |
author_facet | Pawlak-Adamska, Edyta Frydecka, Irena Bolanowski, Marek Tomkiewicz, Anna Jonkisz, Anna Karabon, Lidia Partyka, Anna Nowak, Oskar Szalinski, Marek Daroszewski, Jacek |
author_sort | Pawlak-Adamska, Edyta |
collection | PubMed |
description | Graves’ disease, an autoimmune disease with heterogeneous symptoms including Graves’ orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers. Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302), ICOSc.1554+4GT(8_15) polymorphisms with susceptibility to Graves’ disease and clinical outcome was investigated. The study group comprised of 561 Polish Caucasians, including 172 unrelated Graves’ disease patients. CTLA-4c.49A>G, CTLA-4g.319C>T, and CT60 were genotyped by PCR–RFLP; Jo31 and CD28c.17+3C>T by minisequencing; CTLA-4g.*642AT(8_33) and ICOSc.1554+4GT(8_15)—PCR and fluorescence-based technique. CD28c.17+3T>C(rs3116496)T/CTLA-4g.319C>T(rs5742909)C/CTLA-4c.49A>G(rs231775)G/CTLA-4g.*642AT(8_33)(AT(16–21))/CT60(rs3087243)G/Jo31(rs11571302)G/ICOSc.1554+4GT(8_15)(m) and TCA(AT(<16))GT(m) haplotypes increased risk of Graves’ disease, especially in males, as well as overall Graves’ orbitopathy development with severe outcome. TCG(AT(16–21))GG(l) haplotype increased risk of Graves’ disease and reduced the chance of successful medical treatment. Although this haplotype was mainly observed in patients without signs of Graves’ orbitopathy, if Graves’ orbitopathy developed it favored a Graves’ orbitopathy outcome. Haplotype TCA(AT(>21))GT(m) increased Graves’ disease risk in women and, in all patients, was linked to Graves’ disease without Graves’ orbitopathy. TCG(AT(<16))GG(m) haplotype was predominantly observed in patients without Graves’ orbitopathy, whereas TCA(AT(16–21))GG(m) was absent in those patients. TCA(AT(16–21))GG(m) occurred in patients with a mild Graves’ orbitopathy outcome. The marker CTLA-4g.*642AT(8_33) was the only independent Graves’ disease risk factor, whereas CT60 was an independent factor for disease progression. Sporadic Graves’ disease was related to presence of CTLA-4c.49A>G[A] and the rare CTLA-4g.319C>T[T] allele variant. Familial background of the disease was exclusively associated with CTLA-4g.*642AT(8_33)[AT(>21)]/[AT(>21)] genotype. CD28/CTLA-4/ICOS loci may confer inherited susceptibility to Graves’ disease or may be involved in susceptibility to Graves’ disease and play a pathogenetic role. |
format | Online Article Text |
id | pubmed-5225215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-52252152017-01-24 CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease Pawlak-Adamska, Edyta Frydecka, Irena Bolanowski, Marek Tomkiewicz, Anna Jonkisz, Anna Karabon, Lidia Partyka, Anna Nowak, Oskar Szalinski, Marek Daroszewski, Jacek Endocrine Original Article Graves’ disease, an autoimmune disease with heterogeneous symptoms including Graves’ orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers. Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302), ICOSc.1554+4GT(8_15) polymorphisms with susceptibility to Graves’ disease and clinical outcome was investigated. The study group comprised of 561 Polish Caucasians, including 172 unrelated Graves’ disease patients. CTLA-4c.49A>G, CTLA-4g.319C>T, and CT60 were genotyped by PCR–RFLP; Jo31 and CD28c.17+3C>T by minisequencing; CTLA-4g.*642AT(8_33) and ICOSc.1554+4GT(8_15)—PCR and fluorescence-based technique. CD28c.17+3T>C(rs3116496)T/CTLA-4g.319C>T(rs5742909)C/CTLA-4c.49A>G(rs231775)G/CTLA-4g.*642AT(8_33)(AT(16–21))/CT60(rs3087243)G/Jo31(rs11571302)G/ICOSc.1554+4GT(8_15)(m) and TCA(AT(<16))GT(m) haplotypes increased risk of Graves’ disease, especially in males, as well as overall Graves’ orbitopathy development with severe outcome. TCG(AT(16–21))GG(l) haplotype increased risk of Graves’ disease and reduced the chance of successful medical treatment. Although this haplotype was mainly observed in patients without signs of Graves’ orbitopathy, if Graves’ orbitopathy developed it favored a Graves’ orbitopathy outcome. Haplotype TCA(AT(>21))GT(m) increased Graves’ disease risk in women and, in all patients, was linked to Graves’ disease without Graves’ orbitopathy. TCG(AT(<16))GG(m) haplotype was predominantly observed in patients without Graves’ orbitopathy, whereas TCA(AT(16–21))GG(m) was absent in those patients. TCA(AT(16–21))GG(m) occurred in patients with a mild Graves’ orbitopathy outcome. The marker CTLA-4g.*642AT(8_33) was the only independent Graves’ disease risk factor, whereas CT60 was an independent factor for disease progression. Sporadic Graves’ disease was related to presence of CTLA-4c.49A>G[A] and the rare CTLA-4g.319C>T[T] allele variant. Familial background of the disease was exclusively associated with CTLA-4g.*642AT(8_33)[AT(>21)]/[AT(>21)] genotype. CD28/CTLA-4/ICOS loci may confer inherited susceptibility to Graves’ disease or may be involved in susceptibility to Graves’ disease and play a pathogenetic role. Springer US 2016-09-16 2017 /pmc/articles/PMC5225215/ /pubmed/27638540 http://dx.doi.org/10.1007/s12020-016-1096-1 Text en © The Author(s) 2016 |
spellingShingle | Original Article Pawlak-Adamska, Edyta Frydecka, Irena Bolanowski, Marek Tomkiewicz, Anna Jonkisz, Anna Karabon, Lidia Partyka, Anna Nowak, Oskar Szalinski, Marek Daroszewski, Jacek CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease |
title | CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease |
title_full | CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease |
title_fullStr | CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease |
title_full_unstemmed | CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease |
title_short | CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease |
title_sort | cd28/ctla-4/icos haplotypes confers susceptibility to graves’ disease and modulates clinical phenotype of disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225215/ https://www.ncbi.nlm.nih.gov/pubmed/27638540 http://dx.doi.org/10.1007/s12020-016-1096-1 |
work_keys_str_mv | AT pawlakadamskaedyta cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT frydeckairena cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT bolanowskimarek cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT tomkiewiczanna cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT jonkiszanna cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT karabonlidia cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT partykaanna cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT nowakoskar cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT szalinskimarek cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease AT daroszewskijacek cd28ctla4icoshaplotypesconferssusceptibilitytogravesdiseaseandmodulatesclinicalphenotypeofdisease |